Vaiyapuri P. Sumathi
YOU?
Author Swipe
View article: Malignant Chondroblastoma: An Epigenetically Distinct Subtype of Chondroblastoma With a Predilection for the Skeletally Mature
Malignant Chondroblastoma: An Epigenetically Distinct Subtype of Chondroblastoma With a Predilection for the Skeletally Mature Open
Malignant chondroblastoma is a recently described variant of chondroblastoma showing a distinct age/site distribution and morphology along with the typical H3-3B p.K36M mutation. We sought to further compare conventional and malignant chon…
View article: Correction: Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India
Correction: Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India Open
[This corrects the article DOI: 10.1371/journal.pone.0272042.].
View article: FGF23 Expression Is a Promising Immunohistochemical Diagnostic Marker for Undifferentiated Pleomorphic Sarcoma of Bone (UPSb)
FGF23 Expression Is a Promising Immunohistochemical Diagnostic Marker for Undifferentiated Pleomorphic Sarcoma of Bone (UPSb) Open
Background: Undifferentiated pleomorphic sarcoma of bone (UPSb) is a rare primary bone sarcoma that lacks a specific line of differentiation. Distinguishing between UPSb and other malignant bone sarcomas, including dedifferentiated chondro…
View article: Small cell osteosarcoma versus fusion-driven round cell sarcomas of bone: retrospective clinical, radiological, pathological, and (epi)genetic comparison with clinical implications
Small cell osteosarcoma versus fusion-driven round cell sarcomas of bone: retrospective clinical, radiological, pathological, and (epi)genetic comparison with clinical implications Open
Small cell osteosarcoma (SCOS), a variant of conventional high-grade osteosarcoma (COS), may mimic fusion-driven round cell sarcomas (FDRCS) by overlapping clinico-radiological and histomorphological/immunohistochemical characteristics, ha…
View article: Chondrosarcoma of the Femur: Is Local Recurrence Influenced by the Presence of an Extraosseous Component?
Chondrosarcoma of the Femur: Is Local Recurrence Influenced by the Presence of an Extraosseous Component? Open
Background: Chondrosarcoma (CS) is the second most common surgically treated primary malignancy of the bone. The current study explored the effect of the margin and extraosseous tumor component in CS in the femur on local recurrence (LR), …
View article: Disruption of the <scp> <i>TP53</i> </scp> locus in osteosarcoma leads to <scp> <i>TP53</i> </scp> promoter gene fusions and restoration of parts of the <scp> <i>TP53</i> </scp> signalling pathway
Disruption of the <span> <i>TP53</i> </span> locus in osteosarcoma leads to <span> <i>TP53</i> </span> promoter gene fusions and restoration of parts of the <span> <i>TP53</i> </span> signalling pathway Open
TP53 is the most frequently mutated gene in human cancer. This gene shows not only loss‐of‐function mutations but also recurrent missense mutations with gain‐of‐function activity. We have studied the primary bone malignancy osteosarcoma, w…
View article: Correction to: Bone metastases from chondroblastoma: a rare pattern of metastatic disease in an adult
Correction to: Bone metastases from chondroblastoma: a rare pattern of metastatic disease in an adult Open
View article: Chondrosarcoma of the Proximal Humerus: Does the Margin Affect Survival?
Chondrosarcoma of the Proximal Humerus: Does the Margin Affect Survival? Open
Chondrosarcoma (CS) is the second most common primary malignant bone tumour and, in the absence of reliable chemotherapy and radiotherapy, is effectively a surgical disease. Overall disease specific survival (DSS) is affected by tumour gra…
View article: Figure S2 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Figure S2 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
FACS analysis results for CD24 positivity
View article: Figure S2 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Figure S2 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
FACS analysis results for CD24 positivity
View article: Table S5 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S5 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Mutations found by WES on cases of 5 SEF, 4 SEF/LGFMS and 5 LGFMS; and SEF and SEF/LGFMS mutations confirmed by TSCA.
View article: Figure S1 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Figure S1 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Expression of MUC4 and 11p genes of interest
View article: Data from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Data from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Purpose: Sclerosing epithelioid fibrosarcoma (SEF) is a highly aggressive soft tissue sarcoma closely related to low-grade fibromyxoid sarcoma (LGFMS). Some tumors display morphologic characteristics of both SEF and LGFMS, hence the…
View article: Data from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Data from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Purpose: Sclerosing epithelioid fibrosarcoma (SEF) is a highly aggressive soft tissue sarcoma closely related to low-grade fibromyxoid sarcoma (LGFMS). Some tumors display morphologic characteristics of both SEF and LGFMS, hence the…
View article: Table S1 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S1 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Clinical data
View article: Table S3 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S3 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Differentially expressed genes in sclerosing epithelioid fibrosarcoma (SEF) compared to control tumors and low-grade fibromyxoid sarcoma (LGFMS)
View article: Table S1 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S1 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Clinical data
View article: Table S6 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S6 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Expression of the SEF vs controls 100-top up-regulated genes in Tet-On 3G cells expressing the EWSR1-CREB3L1 fusion
View article: Table S5 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S5 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Mutations found by WES on cases of 5 SEF, 4 SEF/LGFMS and 5 LGFMS; and SEF and SEF/LGFMS mutations confirmed by TSCA.
View article: Table S6 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S6 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Expression of the SEF vs controls 100-top up-regulated genes in Tet-On 3G cells expressing the EWSR1-CREB3L1 fusion
View article: Table S4 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S4 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
SNP array findings in sclerosing epithelioid fibrosarcomas (SEF), hybrid low-grade fibromyxoid sarcomas (LGFMS)/SEF, and LGFMS.
View article: Table S2 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S2 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Primers for RT-PCR detection of gene fusions
View article: Figure S1 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Figure S1 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Expression of MUC4 and 11p genes of interest
View article: Table S2 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S2 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Primers for RT-PCR detection of gene fusions
View article: Table S3 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S3 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
Differentially expressed genes in sclerosing epithelioid fibrosarcoma (SEF) compared to control tumors and low-grade fibromyxoid sarcoma (LGFMS)
View article: Table S4 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Table S4 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets Open
SNP array findings in sclerosing epithelioid fibrosarcomas (SEF), hybrid low-grade fibromyxoid sarcomas (LGFMS)/SEF, and LGFMS.
View article: YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522
YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522 Open
Primary bone cancer (PBC) comprises several subtypes each underpinned by distinctive genetic drivers. This driver diversity produces novel morphological features and clinical behaviour that serendipitously makes PBC an excellent metastasis…
View article: Does the histological presence of a nidus correlate with improved outcomes in osteoid osteoma treated with percutaneous radiofrequency ablation (RFA)?
Does the histological presence of a nidus correlate with improved outcomes in osteoid osteoma treated with percutaneous radiofrequency ablation (RFA)? Open
View article: Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India
Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India Open
Background In the ongoing COVID-19 pandemic, an increased incidence of ROCM was noted in India among those infected with COVID. We determined risk factors for rhino-orbito-cerebral mucormycosis (ROCM) post Coronavirus disease 2019 (COVID-1…
View article: A Multidisciplinary Team Approach Is Highly Effective in the Management of Nondiagnostic Bone Tumour Biopsies: A 10-Year Retrospective Review at a Specialist Sarcoma Unit
A Multidisciplinary Team Approach Is Highly Effective in the Management of Nondiagnostic Bone Tumour Biopsies: A 10-Year Retrospective Review at a Specialist Sarcoma Unit Open
Nondiagnostic (ND) biopsies are frequently encountered during the investigation of bone tumours and can lead to treatment delay. We performed a retrospective review of all ND bone tumour biopsies discussed at our regional MDT meeting betwe…